{'fraction_non_alphanumeric': 0.03277545327754533, 'fraction_numerical': 0.01394700139470014, 'mean_word_length': 5.349557522123894, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Therapeutic efficacy of buforin II and rifampin in a rat model of Acinetobacter baumannii sepsis

Objective: To investigate the efficacy of buforin II and rifampin in an experimental rat model of Acinetobacter baumannii sepsis. Design: Prospective, randomized, controlled animal study. Setting: Research laboratory in a university hospital. Subjects: Adult male Wistar rats. Interventions: The animals received intraperitoneally 1 mL saline containing 2 × 1010 colony forming units of A. baumannii ATCC 19606 (model i) or the multiresistant strain (model ii). Immediately after bacterial challenge, animals received intravenously a single dose of isotonic sodium chloride solution (control groups C1 and C2), 1 mg/kg of buforin II, 10 mg/kg of rifampin, and 1 mg/kg of buforin II plus 10 mg/kg of rifampin, respectively. Measurements and Main Results: Lethality, bacterial growth in blood and tissue burden, endotoxin, interleukin-6, and tumor necrosis factor-&agr; concentrations in plasma. Buforin II showed good antimicrobial activity and achieved a significant reduction of plasma endotoxin and cytokines concentration when compared with control and rifampin-treated groups. Combination among buforin II proved to be the most effective treatment in reducing all variables measured. Conclusion: In an experimental model, buforin II and rifampin might have a potential role in the treatment of severe infections due to A. baumannii.